Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

Jack Power looks at how the war in Iran is involving and the conflict its bringing to European governments. As smoke rises over Tehran from latest strikes, Trump announced that 'we're going to cut off ...

It’s time to pay tribute to an absolute all time classic! The sort of film that just never gets old, regardless of how many times you've watched it, as we’re going to look at the 1995 historical epic ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

Braveheart Bio has officially launched with a mission to transform cardiovascular medicine through advanced small-molecule therapies. The new biotech, led by CEO Travis Murdoch, is backed by leading ...

Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) and ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Braveheart Bio formally debuted on Wednesday with $185 ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

NEW YORK CITY – Curtis Sliwa says he’s charging into the final stretch of New York City’s mayoral race like "Braveheart" — confident, defiant and ready to die on his sword for the city he loves. In an ...

Braveheart Bio has waded into the fight for a heart disease market, paying (PDF) $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten. Jiangsu Hengrui ...